Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc.

Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
FDA cited secondary malignancy risk from another PRC2 inhibitor (Tazverik) withdrawn March 2026.
Company will explore strategic alternatives (merger, acquisition, etc.) and reduce operating expenses.
Held $333.3M in cash, cash equivalents, and marketable securities as of March 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.